» Articles » PMID: 37036742

Association Between Dietary Inflammation Index and Hypertension in Participants with Different Degrees of Liver Steatosis

Overview
Journal Ann Med
Publisher Informa Healthcare
Specialty General Medicine
Date 2023 Apr 10
PMID 37036742
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The prevalence of hypertension (HTN) is higher in patients with non-alcoholic fatty liver disease (NAFLD). Inflammation is the key link between HTN and NAFLD. Systemic inflammation can be dramatically increased by inflammatory diet intake. However, whether controlling the inflammatory diet intake in NAFLD patients could affect the occurrence of HTN still remains unknown. Our aim here is to evaluate the effect of the dietary inflammatory index (DII) on blood pressure in patients with different grades of hepatic steatosis.

Materials And Methods: The data were collected from the National Health and Nutrition Examination Survey (NHANES) (2017-2018). DII was calculated based on the data of 24-h dietary recall interviews. The severity of liver steatosis was assessed by a controlled attenuation parameter. Multivariable logistic regression, multivariable linear regression and subgroup analyses were conducted to determine the association between DII and blood pressure in patients with different degrees of hepatic steatosis.

Results: A total of 5449 participants were included in this analysis. In male participants with severe liver steatosis (S3), the highest DII tertile group was more likely to have higher systolic blood pressure (SBP) compared with the lowest tertile group (Tertile1: 128.31(125.31,131.31), Tertile3: 133.12(129.40,136.85), P for trend =0.03551). DII was positively correlated with SBP and the prevalence of HTN in males with hepatic steatosis grade S3 (≥ 67% steatosis) (SBP: P for trend = 0.011, HTN: P for trend = 0.039). Regarding the association of DII with SBP and HTN, the tests for interaction were significant for hepatic steatosis (SBP: interaction for  = 0.0015, HTN: interaction for  = 0.0202).

Conclusions: In the present study, we demonstrated that DII was a risk factor for increased SBP and the prevalence of HTN in males with severe hepatic steatosis S3, indicating that anti-inflammatory dietary management should be considered in these individuals to reduce the risk of developing HTN.

Citing Articles

Association between neutrophil-to-high-density lipoprotein cholesterol ratio and non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease: evidence from NHANES 2017-2020.

Zhu N, Li Y, Lin Y, Cui X, Li X Front Med (Lausanne). 2025; 11:1491858.

PMID: 39882525 PMC: 11774988. DOI: 10.3389/fmed.2024.1491858.


Higher dietary inflammatory index linked to increased risk of hypertension: a systematic review and dose-response meta-analysis.

Song X, Yang K, Cheng C, Hu Q, Zhao F, Lu S Eur J Clin Nutr. 2024; .

PMID: 39448814 DOI: 10.1038/s41430-024-01530-9.


The Association Between Neutrophil/High-Density Lipoprotein Cholesterol Ratio and Non-Alcoholic Fatty Liver Disease in a Healthy Population.

Jia Z, Li Z, Chen S Diabetes Metab Syndr Obes. 2024; 17:2597-2605.

PMID: 38946914 PMC: 11214802. DOI: 10.2147/DMSO.S464406.


Association between liver fat level and risk of hypertension: evidence from a Chinese health examination dataset.

Sun Y, Qi X, Wang X, Lin X, Zhou Y, Du Y J Hypertens. 2024; 42(10):1785-1794.

PMID: 38920061 PMC: 11356678. DOI: 10.1097/HJH.0000000000003803.


Dietary inflammatory impact on NAFLD development in obese vs. lean individuals: an analysis based on NHANES 2003-2018.

Li L, Shu X, Yi Y, Wang C, Li J, Ding Y Lipids Health Dis. 2024; 23(1):127.

PMID: 38685122 PMC: 11619212. DOI: 10.1186/s12944-024-02082-4.


References
1.
Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G . Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertension. 2020; 76(2):562-568. DOI: 10.1161/HYPERTENSIONAHA.120.15220. View

2.
Knowlton A, Lee A . Estrogen and the cardiovascular system. Pharmacol Ther. 2012; 135(1):54-70. PMC: 5688223. DOI: 10.1016/j.pharmthera.2012.03.007. View

3.
Nunes K, Almeida de Oliveira A, Mowry F, Biancardi V . Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the toll for hypertension?. Br J Pharmacol. 2018; 176(12):1864-1879. PMC: 6534778. DOI: 10.1111/bph.14438. View

4.
Vasunta R, Kesaniemi Y, Ylitalo A, Ukkola O . High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults. J Hypertens. 2012; 30(10):2015-9. DOI: 10.1097/HJH.0b013e3283576faf. View

5.
. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017; 49(5):471-483. DOI: 10.1016/j.dld.2017.01.147. View